The Porcine Pulmonary Surfactant Protein A (pSP-A) Immunogenicity Evaluation in the Murine Model

Sandra de Cássia Dias, Fernanda Lucio dos Santos, Dirce Sakauchi, Dmitri Iourtov, Isaias Raw, Flavia Saldanha Kubrusly

.

DOI: 10.4236/pp.2010.11004                

Abstract

This paper investigated the porcine surfactant protein A (pSP-A) immunogenicity in murine model. Many elegant stu-dies about SP-A therapeutic applications are available however specific studies about its exogenous immunogenicity were not easily assumed. Therefore, we investigated the immunogenicity of this porcine protein in mice. The mice re-ceived pSP-A subcutaneously on days 0 and 7. The animals were observed during 90 days and the blood was collected on days 30, 60 and 90 for assessment the immunogenic potential of pSP-A. Some animals showed circulating antibodies above the screening cut point, which was calculated based on control mice sera signals. However, those antibodies were considered false positive read-outs by the performed competitive inhibition assay. Also no neutralizing antibodies were detected able to avoid the porcine protein ability to promote lipid aggregation. So far in this model, porcine surfactant protein-A could be considered not immunogenic.

Keywords

Immunogenicity, Porcine Surfactant Protein A, Anti-Drug Antibody, Murine Model

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	P. Waters, M. Vaid, U. Kishore and T. Madan, “Lung Surfactant Proteins A and D as a Pattern Recognition Proteins,” Advances in Experimental Medicine Biology, Vol. 653, December 2009, pp. 74-97.
[2]	N. Palaniyar, J. Nadesalingam, H. Clark, M. J. Shih, A. W. Dodds and K. B. Reid, “Nucleic Acid is a Novel Ligand for Innate, Immune Pattern Recognition Collectins Surfactant Proteins A and D and Mannose-Binding Lec-tin,” The Journal of Biological Chemistry, Vol. 279, No. 31, May 2004, pp. 32728-32736.
[3]	A. Haczku, “Protective Role of the Lung Collectins Sur-factant Protein A and Surfactant Protein D in Airway In-flammation,” The Journal of Allergy and Clinical Immu-nology, Vol. 122, No. 5, November 2008, pp. 861-879.
[4]	M. E. Famuyide, J. D. Hasday, H. C. Carter, K. L. Chesko, J. R. He and R. M. Viscardi, “Surfactant Protein-A Limits Ureaplasma-Mediated Lung Inflammation in a Murine Pneumonia Model,” Pediatric Research, Vol. 66, No. 2, August 2009, pp. 162-167.
[5]	S. G. Kremlev and D. S. Phelps, “Surfactant Protein A Stimulation of Inflammatory Cytokine and Immunoglo-bulin Production,” American Journal Physiology, Vol. 267, No. 6, December 1994, pp. L712-L719.
[6]	G. Schernthaner, “Immunogenicity and Allergenic Poten-tial of Animal and Human Insulins,” Diabetes Care, Vol. 16, Suppl. 3, December 1993, pp. 155-165.
[7]	E-V. Jahn, C. K. Schneider, “How to Systematically Evaluate Immunogenicity of Therapeutic Proteins— Regulatory Considerations,” New Biotechnology, Vol. 25, No. 5, June 2009, pp. 280-286.
[8]	G. Shankar, V. Devanarayan, L. Amaravadi, Y. C. Barrett, R. Bowsher, D. Finco-Kent, M. Fiscella, B. Gorovits, S. Kirschner, M. Moxness, T. Parish, V. Quarmby, H. Smith, W. Smith, L. A. Zuckerman and E. Koren, “Recommen-dations for the Validation of Immunoassays Used for De-tection of Host Antibodies against Biotechnology Prod-ucts,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 48, No. 5, December 2008, pp. 1267-1281.
[9]	M. L. F. Ruano, E. Miguel, J. Perez-Gil and C. Casals, “Comparison of Lipid Aggregation and Self-Aggregation Activities of Pulmonary Surfactant Associated Protein A,” Biochemical Journal, Vol. 313, Part 2, January 1986, pp. 683-689.
[10]	F. Sánchez-Barbero, J. Strassner, R. García-Canero, W. Steinhilber and C. Casals, “Role of the Degree of Oligo-merization in the Structure and Function of Human Sur-factant Protein,” The Journal of Biological Chemistry, Vol. 280, No. 9, March 2005, pp. 7659-7670.
[11]	H. P. Haagsman, A. Hogenkamp, M. van Eijk and E. J. Veldhuizen, “Surfactant Collectins and Innate Immunity,” Neonatology, Vol. 93, No. 4, June 2008, pp. 288-294.